Rocket Pharmaceuticals Inc

RCKT

Company Profile

  • Business description

    Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

  • Contact

    9 Cedarbrook Drive
    CranburyNJ08512
    USA

    T: +1 609 659-8001

    E: [email protected]

    https://www.rocketpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    299

Stocks News & Analysis

stocks

Going into earnings, is Netflix stock a buy, a sell, or fairly valued?

Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks

Bapcor is paying for the sins of its past

Shares plunged over 17% after reporting disappointing results.
stocks

Overvalued ASX share as market underestimates downside risks

Growth outlook solid, but upside more than priced in.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,393.0019.300.21%
CAC 408,206.0717.480.21%
DAX 4024,258.80427.811.80%
Dow JONES (US)46,706.58515.971.12%
FTSE 1009,403.5749.000.52%
HKSE25,858.83611.732.42%
NASDAQ22,990.54310.571.37%
Nikkei 22549,648.61463.110.94%
NZX 50 Index13,324.4820.48-0.15%
S&P 5006,735.1371.121.07%
S&P/ASX 2009,091.5015.600.17%
SSE Composite Index3,863.8924.140.63%

Market Movers